Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A genomewide map of PPARb/d target genes in human macrophages identifies a unique agonist-induced activation state - RNAseq

ABSTRACT: A genomewide map of PPARb/d target genes in human macrophages identifies a unique agonist-induced activation state - RNAseq

PROVIDER: PRJEB7829 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR688002.fastq.gz	Fastqsanger.gz
	ERR688003.fastq.gz	Fastqsanger.gz
	ERR688004.fastq.gz	Fastqsanger.gz
	ERR688005.fastq.gz	Fastqsanger.gz
	ERR688006.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 6

Similar Datasets

A genomewide map of PPARb/d target genes in human macrophages identifies a unique agonist-induced activation state - RNAseq

Project description:PPARb/d agonist and antagonist response was characterized in (human) monocyte derived macrophages.

2015-12-02 | E-MTAB-3114 | biostudies-arrayexpress

Synthetic RIG-I agonist-mediated cancer immunotherapy synergizes with MAP-Kinase inhibition against BRAF mutated melanoma

Project description:The implementations of targeted molecular therapies and immunotherapy in melanoma vastly improved the therapeutic outcome in patients with limited efficacy of surgical intervention. Nevertheless, a large fraction of melanoma patients still remains refractory or acquires resistance to these new forms of treatment, illustrating a need for improvement. Here we report that the clinically relevant combination of MAP kinase inhibitors Dabrafenib and Trametinib synergizes with RIG-I agonist-induced immunotherapy to kill BRAF-mutated human and mouse melanoma cells. Kinase inhibition did not compromise the agonist-induced innate immune response of the RIG-I pathway in host immune cells. In a melanoma transplantation mouse model, the triple therapy outperformed the individual therapies. Our study suggests that targeted activation of RIG-I with its synthetic ligand 3pRNA could vastly improve tumor control in a substantial fraction of melanoma patients receiving MAP kinase inhibitors.

2024-07-26 | GSE268982 | GEO

Synthetic RIG-I agonist-mediated cancer immunotherapy synergizes with MAP-Kinase inhibition against BRAF mutated melanoma [YUMM1.7]

2024-06-04 | GSE269008 | GEO

Genomewide methylation profiles in coronary artery ectasia

Project description:Genomewide methylation profiles in coronary artery ectasia patients and matched healthy controls.

2017-12-21 | GSE87016 | GEO

Genomewide methylation analysis in Silver Russell syndrome patients

Project description:Genomewide methylation analysis in Silver Russell syndrome patients compared to healthy controls

2015-01-12 | GSE55491 | GEO

Genomewide identification of ANAC060 binding targets

Project description:Genomewide identification of ANAC060 binding targets

| PRJNA507758 | ENA

Genomewide poly(A) site mapping for YJR141W and related mutants

Project description:Genomewide characterization of YJR141W role in mRNA polyadenylation.

2017-05-08 | GSE60947 | GEO

Synthetic RIG-I agonist-mediated cancer immunotherapy synergizes with MAP-Kinase inhibition against BRAF mutated melanoma

Project description:Synthetic RIG-I agonist-mediated cancer immunotherapy synergizes with MAP-Kinase inhibition against BRAF mutated melanoma

| PRJNA1119558 | ENA

A genomewide admixture map for Latino populations.

Project description:Admixture mapping is an economical and powerful approach for localizing disease genes in populations of recently mixed ancestry and has proven successful in African Americans. The method holds equal promise for Latinos, who typically inherit a mix of European, Native American, and African ancestry. However, admixture mapping in Latinos has not been practical because of the lack of a map of ancestry-informative markers validated in Native American and other populations. To address this, we screened multiple databases, containing millions of markers, to identify 4,186 markers that were putatively informative for determining the ancestry of chromosomal segments in Latino populations. We experimentally validated each of these markers in at least 232 new Latino, European, Native American, and African samples, and we selected a subset of 1,649 markers to form an admixture map. An advantage of our strategy is that we focused our map on markers distinguishing Native American from other ancestries and restricted it to markers with very similar frequencies in Europeans and Africans, which decreased the number of markers needed and minimized the possibility of false disease associations. We evaluated the effectiveness of our map for localizing disease genes in four Latino populations from both North and South America.

| S-EPMC1867092 | biostudies-literature

ANKRD52_SHAPE-MaP

Project description:ANKRD52_SHAPE-MaP

| PRJNA762350 | ENA